RSV in Young Children During and After the COVID-19 Pandemic-Implications for Delaying the Age of First Infection.

Nonpharmaceutical interventions introduced in the United Kingdom's response to the COVID-19 pandemic disrupted the transmission of other childhood infections. We report changes in seasonality, age dynamics and severity of respiratory syncytial virus infections between 2019 and 2023. These data show the potential effects of delaying respiratory syncytial virus exposure and may provide insights for the implementation of treatments preventing infection during early infancy.

The diagnostic accuracy of the ID NOW COVID-19 point of care test in acute hospital admissions.

Background: Prompt identification of patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection on admission to hospital is crucial to ensuring initiation of appropriate treatment, optimising infection control and maintaining patient flow. The Abbott ID NOW™ COVID-19 assay (ID NOW) is a point-of-care, isothermal nucleic acid amplification test, capable of producing a result within minutes, potentially placing it as an invaluable tool in helping to control the coronavirus-disease 2019 (COVID-19) pandemic.

Objectives: To evaluate the diagnostic accuracy of ID NOW in acute hospital admissions.